Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: J Invest Dermatol. 2014 Jan 24;134(6):1725–1734. doi: 10.1038/jid.2014.40

Figure 5. Kallistatin reduces Wnt3a-induced dermal endothelial cell angiogenesis and Wnt3a-induced TCF/β-catenin-dependent transcription.

Figure 5

In vitro angiogenesis assay, primary HDMVECs; (a) 30% LCM + 25 μg/mL BSA; 30% WCM + 25 μg/mL BSA; 30% WCM + 25 μg/mL kallistatin (KS); (b) total tube length quantification; (c) branch points; (d) HDMVECs treated simultaneously with 30% WCM and purified KS or BSA, 48 hr. Cell viability via MTT assay; (e) Western blot analysis, phosphorylated LRP6 (Pi-LRP6); HDMVECs; (f) HDMVECs, infected with lentivirus expressing luciferase driven by TCF/β-catenin (renilla luciferase for normalization). HDMVECs were treated with 30% LCM or 30% WCM and different concentrations of KS for 16 hr. (g) vegf-a mRNA levels in HDMVECs treated as indicated for 16 hr. Mean ± S.E.M., *p<0.05; **<0.01; ***p<0.001.